Annamaria Muraro

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate – a “fixed triple”. This two-part study was randomized, double blind, placebo controlled in patients with moderate-to-severe COPD: Part 1: single-dose escalation, GB 12.5, 25, 50, 100 or 200 μg versus placebo; Part 2: repeat-dose (7-day), four-period crossover, GB 12.5, 25 or 50 μg twice daily (BID) versus placebo, with an open-label extension in which all patients received tiotropium 18 μg once daily. On the morning of Day 8 in all five periods, patients also received formoterol 12 μg. In study Part 1, 27 patients were recruited. All GB doses significantly increased from baseline forced expiratory volume in 1 second (FEV1) area under the curve (AUC0–12h) and peak FEV1, with a trend toward greater efficacy with higher GB dose. All adverse events were mild–moderate in severity, with a lower incidence with GB than placebo and no evidence of a dose–response relationship. In study Part 2, of 38 patients recruited, 34 completed the study. Adjusted mean differences from placebo in 12 h trough FEV1 on Day 7 (primary) were 115, 142 and 136 mL for GB 12.5, 25 and 50 μg BID, respectively (all P<0.001). GB 25 and 50 μg BID were superior (P<0.05) to GB 12.5 μg BID for pre-dose morning FEV1 on Day 8. For this endpoint, GB 25 and 50 μg BID were also superior to tiotropium. Compared with Day 7, addition of formoterol significantly increased Day 8 FEV1 peak and AUC0–12h with all GB doses and placebo (all P<0.001). All adverse events were mild–moderate in severity and there was no indication of a dose-related relationship. This study provides initial evidence on bronchodilation, safety and pharmacokinetics of extrafine GB BID. Overall, the results suggest that GB 25 μg BID is the optimal dose in patients with COPD.

P271 Effect of extrafine single inhaler triple therapy on lung function and use of rescue medication: results from the trinity study

Rationale Treatment with extrafine triple therapy in a single inhaler has beneficial effects compared to LAMA monotherapy on lung function and symptoms. This analysis focuses on rescue medication use (as this is associated with symptoms) and lung function responder analysis identifying clinically relevant effects. Methods In this 52 week multicentre, randomised, double-blind, active-controlled study, 2691 patients with severe to very severe COPD, exacerbations history, and CAT total score ≥10 were randomised (2:2:1) to tiotropium, fixed triple (beclometasone/formoterol/glycopyrronium), or free triple (beclometasone/formoterol+tiotropium). Secondary endpoints included FEV1 responders at week 26 and 52 using different thresholds for response and change from baseline in average use of rescue medication. Results Both fixed and free triple FEV1 responder percentages were significantly greater than tiotropium at weeks 26 and 52 regardless of the threshold used to define the response (p<0.001 for all analyses). At 26 weeks the proportion of responders were 48.0% (fixed triple) and 48.1% (free triple) for the 50 ml threshold, and 36.7% and 34.8% at the higher 120 mL threshold, with similar Results at week 52. Corresponding FEV1 responder percentages for tiotropium were lower at the 50 mL threshold (35.7% and 34.8%, at weeks 26 and 52 respectively) and 120 mL threshold (25.3% and 24.8%, respectively). In terms of average percentage of days without rescue medication use over 52 weeks, all treatments showed statistically significant increases from baseline which were more marked with fixed and free triple (13.9 [95%CI: 12;15.8] and 14.8% [95%CI: 12.1;17.4] respectively) compared to 5.2% [95%CI: 3.3;7.1] for tiotropium alone (p<0.001) and no difference observed between fixed and free triple with an adjusted mean difference of −0.8% [95% CI: −4.1;2.4] (p=0.616). Average use of rescue medication with both fixed and free triple treatments over 52 weeks compared to tiotropium alone was reduced by 0.6 [95%CI: 0.4;0.7] and 0.6 [95%CI: 0.5;0.8] puffs/day, respectively (p<0.001). Conclusions Extrafine triple therapy in a single inhaler provides superior clinical benefits in severe to very severe COPD patients in terms of lung function (by individual responder analysis) and rescue medication use compared with tiotropium alone. Please refer to page A260 for declarations of interest in relation to abstract P271.

P273 Association of incident pneumonia and exacerbations with extrafine triple therapy in one single inhaler in copd patients: a post-hoc analysis from trilogy and trinity studies

Rationale Efficacy and safety of extrafine fixed triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; 100/6/12.5 mcg, two actuations BID via pMDI; ‘fixed triple’) has been recently demonstrated in two phase III trials. Fixed triple has shown superiority in improving lung function and reducing moderate/severe exacerbations versus BDP/FF (Fostair 100/6 mcg, two actuations BID via pMD; TRILOGY – Singh et al. Lancet 2016; 388: 963–73) and versus tiotropium (18 mcg one inhalation OD via DPI; TRINITY – Vestbo et al. Lancet 2017; 389: 1919–29). Increase in pneumonia risk associated with ICS containing medications is a known class effect. The risk/benefit balance of extrafine fixed triple was evaluated by comparing variations in pneumonia and exacerbation events. Methods Information on moderate/severe exacerbations and confirmed pneumonia was extracted from TRINITY and TRILOGY. A frequency plot was generated considering days in the study versus cumulative number of events. Results In TRILOGY study, the number of recorded events was 288 exacerbations (rate: 0.448 exacerbations per patient per year) versus 25 pneumonias (rate: 0.039 events per patient per year) with fixed triple and 353 exacerbations (0.565) versus 18 pneumonias (0.029) with Fostair (figure 1A). In TRINITY study, the number of events was 485 exacerbations (0.472) versus 30 pneumonias (0.029) with fixed triple and 569 exacerbations (0.583) versus 20 pneumonias (0.020) with tiotropium (figure 1B). Overall, treatment with fixed triple therapy reduced exacerbations by 65 events compared to Fostair (adjusted rate ratio: 0.773, p=0.005) and by 84 events compared to tiotropium (0.801, p=0.003). No fatal pneumonias occurred in TRILOGY while 5 pneumonias led to death in TRINITY (1 with fixed triple versus 4 with tiotropium). All pneumonias were classified as non-related to treatment. Conclusions This analysis confirms that, in two independent populations of COPD patients treated with an ICS containing extrafine fixed triple combination, the number of incident pneumonia remains very small compared to that of moderate/severe exacerbations. The benefit observed in reducing the absolute number of exacerbations outweighs the increase observed in absolute number of pneumonias, thus confirming the positive risk benefit balance of extrafine fixed triple in severe/very severe COPD patients. Please refer to page A260 for declarations of interest in relation to abstract P273.

P276 Cardiovascular safety of extrafine single inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide in copd: results of safety analysis from the trilogy and trinity studies

Rationale COPD often co-exists with other chronic diseases that can contribute to patients’ health status and prognosis. In particular, patients with COPD are at greater risk of cardiovascular disease compared with age and sex-matched controls. Methods Two 52 week multi-centre, randomised, double-blind, active-controlled studies recruited patients with symptomatic COPD, severe to very severe airflow limitation, and an exacerbation history. In TRILOGY, patients were randomised (1:1) to an extrafine fixed triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; 100/6/12.5 mcg, two actuations twice daily [BID] via pressurised metered dose inhaler [pMDI]; ‘fixed triple’) or an extrafine fixed combination of BDP/FF (100/6 mcg, two actuations BID via pMDI; Fostair) (Singh et al. Lancet 2016; 388: 963–73). In TRINITY patients were randomised 2:2:1 to BDP/FF/GB, tiotropium (18 mcg once daily via single-dose dry powder inhaler [SDDPI]), or BDP/FF+tiotropium: free triple (Vestbo et al. Lancet 2017; 389: 1919–29). In this analysis, we evaluated the occurrence of Major Adverse Cardiovascular Events (MACEs). MACEs included acute myocardial infarction, stroke, cardiovascular death, arrhythmias, and heart failure. Results MACE incidence and rate in the two BDP/FF/GB groups was similar to the BDP/FF and tiotropium groups (Table 1). The majority of reported MACEs were severe in intensity, with a slightly higher percentage of fatal events in the Tiotropium only group. Importantly, in patients with relevant concomitant cardiovascular diseases, the trend was similar to that seen in the overall populations. None of the other subgroup analyses (by age, spacer use and gender) highlighted relevant differences in the safety profiles compared with the overall population. Conclusions These Results provide further reassurance that the additional clinical benefits of this extrafine fixed triple compared to standard treatment are not associated with a greater impact on the cardiovascular safety in severe to very severe COPD patients, further supporting its positive benefit/risk ratio. Importantly, the presence of concomitant cardiac comorbidities did not influence the rate of cardiovascular events. Please refer to page A261 for declarations of interest in relation to abstract P276. Abstract P276 Table 1 Patients (%) with MACE, and MACE rate per 1000 patient years in TRILOGY and TRINITY TRILOGY TRINITY BDP/FF/GB (Fixed Triple)(n=687) BDP/FF (Fostair®)(n=680) BDP/FF/GB (Fixed Triple)(n=1077) Tiotropium (n=1076) BDP/FF+ Tiotropium (Free Triple)n=537 Treatment-emergent MACEs, n(%) 15 (2.2%) 15 (2.2%) 20 (1.9%) 23 (2.1%) 7 (1.3%) Acute Myocardial infarction 1 (0.1%) 6 (0.9%) 2 (0.2%) 4 (0.4%) 0 Arrhythmias 3 (0.4%) 2 (0.3%) 1 (0.1%) 1 (0.1%) 1 (0.2%) Cardiovascular death 3 (0.4%) 3 (0.4%) 8 (0.7%) 6 (0.6%) 2 (0.4%) Heart failure 6 (0.9%) 3 (0.4%) 0 8 (0.7%) 2 (0.4%) Stroke 2 (0.3%) 2 (0.3%) 9 (0.8%) 3 (0.3%) 2 (0.4%) Unknown cause of death 0 0 0 1 (0.1%) 0 Any fatal MACE 4 (0.6%) 5 (0.7%) 10 (0.9%) 12 (1.1%) 2 (0.4%) MACE rate per 1000 patient years 24.9 25.6 19.5 23.5 13.6